Literature DB >> 22695045

Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study.

Shalini Dalal1, David Hui, Luc Bidaut, Kristen Lem, Egidio Del Fabbro, Christopher Crane, Cielito C Reyes-Gibby, Deepak Bedi, Eduardo Bruera.   

Abstract

CONTEXT: In pancreatic cancer, the presence of obesity or weight loss is associated with higher mortality.
OBJECTIVES: To explore the relationships among body mass index, longitudinal body composition alterations, and clinical outcomes in pancreatic cancer patients.
METHODS: Records of 41 patients with inoperable locally advanced pancreatic cancer who participated in a prospective chemoradiation study were reviewed. Body composition was analyzed from two sets of computed tomography images obtained before and after radiation treatment (median interval 104 days).
RESULTS: Median age was 59 years and 56% of patients were female. Twenty-four (59%) patients were either overweight (22%) or obese (37%). Sarcopenia was present in 26 (63%) patients. At follow-up, weight loss was experienced by 33 (81%) patients. The median losses (%) before and after treatment were weight 5% (P<0.001), skeletal muscle (SKM) 4% (P=0.003), visceral adipose tissue (VAT) 13% (P<0.001), and subcutaneous adipose tissue 11% (P=0.002). SKM loss positively correlated with age (P=0.03), baseline body mass index (P<0.001), and VAT (P=0.04) index. Obese patients experienced higher losses in weight (P=0.009), SKM (P=0.02), and VAT (P=0.02). Median survival was 12 months. In univariate analysis, age, baseline obesity, sarcopenic obesity, and losses (%) in weight, SKM, and VAT were associated with worse survival. In multivariate analysis, only age (hazard ratio=1.033, P=0.04) and higher VAT loss (hazard ratio=2.6 and P=0.03) remained significant.
CONCLUSION: Our preliminary findings suggest that obese patients experience higher losses in weight, SKM, and VAT, which may contribute to poorer survival in these patients.
Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22695045      PMCID: PMC3990439          DOI: 10.1016/j.jpainsymman.2011.09.010

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  52 in total

1.  Cancer cachexia and fat-muscle physiology.

Authors:  Kenneth C H Fearon
Journal:  N Engl J Med       Date:  2011-08-11       Impact factor: 91.245

Review 2.  Systemic inflammation, cachexia and prognosis in patients with cancer.

Authors:  Christopher Deans; Stephen J Wigmore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-05       Impact factor: 4.294

3.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

4.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

Authors:  H J Andreyev; A R Norman; J Oates; D Cunningham
Journal:  Eur J Cancer       Date:  1998-03       Impact factor: 9.162

5.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

6.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

7.  Diminished visceral adipose tissue in cancer cachexia.

Authors:  H Ogiwara; S Takahashi; Y Kato; I Uyama; T Takahara; K Kikuchi; S Iida
Journal:  J Surg Oncol       Date:  1994-10       Impact factor: 3.454

Review 8.  Zinc-alpha2-glycoprotein in cachexia and obesity.

Authors:  Michael J Tisdale
Journal:  Curr Opin Support Palliat Care       Date:  2009-12       Impact factor: 2.302

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  Adipose triglyceride lipase contributes to cancer-associated cachexia.

Authors:  Suman K Das; Sandra Eder; Silvia Schauer; Clemens Diwoky; Hannes Temmel; Barbara Guertl; Gregor Gorkiewicz; Kuppusamy P Tamilarasan; Pooja Kumari; Michael Trauner; Robert Zimmermann; Paul Vesely; Guenter Haemmerle; Rudolf Zechner; Gerald Hoefler
Journal:  Science       Date:  2011-06-16       Impact factor: 47.728

View more
  47 in total

1.  Change in Skeletal Muscle Following Resection of Stage I-III Colorectal Cancer is Predictive of Poor Survival: A Cohort Study.

Authors:  Jessica J Hopkins; Rebecca Reif; David Bigam; Vickie E Baracos; Dean T Eurich; Michael M Sawyer
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

Review 2.  Chemotherapy-Induced Sarcopenia.

Authors:  Federico Bozzetti
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

Review 3.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

4.  Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer.

Authors:  Ana Babic; Michael H Rosenthal; Gloria M Petersen; Brian M Wolpin; William R Bamlet; Naoki Takahashi; Motokazu Sugimoto; Laura V Danai; Vicente Morales-Oyarvide; Natalia Khalaf; Richard F Dunne; Lauren K Brais; Marisa W Welch; Caitlin L Zellers; Courtney Dennis; Nader Rifai; Carla M Prado; Bette Caan; Tilak K Sundaresan; Jeffrey A Meyerhardt; Matthew H Kulke; Clary B Clish; Kimmie Ng; Matthew G Vander Heiden
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-18       Impact factor: 4.254

5.  Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma.

Authors:  Ilaria Trestini; Salvatore Paiella; Claudio Bassi; Michele Milella; Marta Sandini; Isabella Sperduti; Giovanni Elio; Tommaso Pollini; Davide Melisi; Alessandra Auriemma; Caterina Soldà; Clelia Bonaiuto; Daniela Tregnago; Alice Avancini; Erica Secchettin; Deborah Bonamini; Massimo Lanza; Sara Pilotto; Giuseppe Malleo; Roberto Salvia; Chiara Bovo; Luca Gianotti
Journal:  Ann Surg Oncol       Date:  2020-05-09       Impact factor: 5.344

6.  Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance.

Authors:  Paul T Winnard; Santosh K Bharti; Marie-France Penet; Radharani Marik; Yelena Mironchik; Flonne Wildes; Anirban Maitra; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

7.  Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice.

Authors:  Kara L Kliewer; Jia-Yu Ke; Min Tian; Rachel M Cole; Rebecca R Andridge; Martha A Belury
Journal:  Cancer Biol Ther       Date:  2014-12-02       Impact factor: 4.742

Review 8.  Prognostication in advanced cancer: update and directions for future research.

Authors:  David Hui; Carlos Eduardo Paiva; Egidio G Del Fabbro; Christopher Steer; Jane Naberhuis; Marianne van de Wetering; Paz Fernández-Ortega; Tatsuya Morita; Sang-Yeon Suh; Eduardo Bruera; Masanori Mori
Journal:  Support Care Cancer       Date:  2019-03-13       Impact factor: 3.603

Review 9.  Clinical Implications of Sarcopenic Obesity in Cancer.

Authors:  Isabella P Carneiro; Vera C Mazurak; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

10.  Loss of muscle mass in the end of life in patients with advanced cancer.

Authors:  Ola Wallengren; Britt-Marie Iresjö; Kent Lundholm; Ingvar Bosaeus
Journal:  Support Care Cancer       Date:  2014-07-01       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.